BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 24605021)

  • 1. Opioid growth factor and the treatment of human pancreatic cancer: a review.
    Zagon IS; McLaughlin PJ
    World J Gastroenterol; 2014 Mar; 20(9):2218-23. PubMed ID: 24605021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination chemotherapy with gemcitabine and biotherapy with opioid growth factor (OGF) enhances the growth inhibition of pancreatic adenocarcinoma.
    Zagon IS; Jaglowski JR; Verderame MF; Smith JP; Leure-Dupree AE; McLaughlin PJ
    Cancer Chemother Pharmacol; 2005 Nov; 56(5):510-20. PubMed ID: 15947928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell proliferation of human ovarian cancer is regulated by the opioid growth factor-opioid growth factor receptor axis.
    Donahue RN; McLaughlin PJ; Zagon IS
    Am J Physiol Regul Integr Comp Physiol; 2009 Jun; 296(6):R1716-25. PubMed ID: 19297547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Growth inhibition of thyroid follicular cell-derived cancers by the opioid growth factor (OGF) - opioid growth factor receptor (OGFr) axis.
    McLaughlin PJ; Zagon IS; Park SS; Conway A; Donahue RN; Goldenberg D
    BMC Cancer; 2009 Oct; 9():369. PubMed ID: 19835629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The OGF-OGFr axis utilizes the p21 pathway to restrict progression of human pancreatic cancer.
    Cheng F; McLaughlin PJ; Verderame MF; Zagon IS
    Mol Cancer; 2008 Jan; 7():5. PubMed ID: 18190706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Opioid growth factor receptor is unaltered with the progression of human pancreatic and colon cancers.
    Zagon IS; McLaughlin PJ
    Int J Oncol; 2006 Aug; 29(2):489-94. PubMed ID: 16820893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The opioid growth factor-opioid growth factor receptor axis: homeostatic regulator of cell proliferation and its implications for health and disease.
    McLaughlin PJ; Zagon IS
    Biochem Pharmacol; 2012 Sep; 84(6):746-55. PubMed ID: 22687282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of Tenon's capsule fibroblast cell proliferation by the opioid growth factor and the opioid growth factor receptor axis.
    Klocek MS; Sassani JW; Donahue RN; McLaughlin PJ; Zagon IS
    Invest Ophthalmol Vis Sci; 2010 Oct; 51(10):5054-61. PubMed ID: 20463323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Opioid growth factor-opioid growth factor receptor axis is a physiological determinant of cell proliferation in diverse human cancers.
    Zagon IS; Donahue RN; McLaughlin PJ
    Am J Physiol Regul Integr Comp Physiol; 2009 Oct; 297(4):R1154-61. PubMed ID: 19675283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Featured Article: Modulation of the OGF-OGFr pathway alters cytokine profiles in experimental autoimmune encephalomyelitis and multiple sclerosis.
    Ludwig MD; Zagon IS; McLaughlin PJ
    Exp Biol Med (Maywood); 2018 Feb; 243(4):361-369. PubMed ID: 29307283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. B lymphocyte proliferation is suppressed by the opioid growth factor-opioid growth factor receptor axis: Implication for the treatment of autoimmune diseases.
    Zagon IS; Donahue RN; Bonneau RH; McLaughlin PJ
    Immunobiology; 2011; 216(1-2):173-83. PubMed ID: 20598772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of the opioid growth factor receptor potentiates growth inhibition in human pancreatic cancer cells.
    Zagon IS; Verderame MF; Hankins J; McLaughlin PJ
    Int J Oncol; 2007 Apr; 30(4):775-83. PubMed ID: 17332915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective oncotarget for gynecological cancer: Opioid growth factor (OGF) - opioid growth factor receptor (OGFr) axis.
    Qu N; Wang X; Meng Y; Shan F
    Int Immunopharmacol; 2019 Oct; 75():105723. PubMed ID: 31408839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The opioid growth factor (OGF)-OGF receptor axis uses the p16 pathway to inhibit head and neck cancer.
    Cheng F; Zagon IS; Verderame MF; McLaughlin PJ
    Cancer Res; 2007 Nov; 67(21):10511-8. PubMed ID: 17974995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of opioid growth factor (OGF)-OGF receptor (OGFr) axis in human nonmedullary thyroid cancer.
    Goldenberg D; Zagon IS; Fedok F; Crist HS; McLaughlin PJ
    Thyroid; 2008 Nov; 18(11):1165-70. PubMed ID: 19014324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Astrocyte proliferation is regulated by the OGF-OGFr axis in vitro and in experimental autoimmune encephalomyelitis.
    Campbell AM; Zagon IS; McLaughlin PJ
    Brain Res Bull; 2013 Jan; 90():43-51. PubMed ID: 22985690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The OGF-OGFr axis utilizes the p16INK4a and p21WAF1/CIP1 pathways to restrict normal cell proliferation.
    Cheng F; McLaughlin PJ; Verderame MF; Zagon IS
    Mol Biol Cell; 2009 Jan; 20(1):319-27. PubMed ID: 18923142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Opioid growth factor (OGF) inhibits anchorage-independent growth in human cancer cells.
    Zagon IS; McLaughlin PJ
    Int J Oncol; 2004 Jun; 24(6):1443-8. PubMed ID: 15138586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The opioid growth factor (OGF) and low dose naltrexone (LDN) suppress human ovarian cancer progression in mice.
    Donahue RN; McLaughlin PJ; Zagon IS
    Gynecol Oncol; 2011 Aug; 122(2):382-8. PubMed ID: 21531450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutations in the opioid growth factor receptor in human cancers alter receptor function.
    Kren NP; Zagon IS; McLaughlin PJ
    Int J Mol Med; 2015 Jul; 36(1):289-93. PubMed ID: 26005722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.